Consensus in acute myeloid leukemia in Mexico
Luara L Arana-Luna1, Martha Alvarado-Ibarra1, Luis G Silva-Michel2
1Servicio de Hematología, Centro Médico Nacional 20 de Noviembre, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE), Mexico City, Mexico.
Abstract:
Acute myeloid leukemia (AML) comprises a heterogeneous group of hematopoietic cell neoplasms of myeloid lineage that arise from the clonal expansion of their precursors in the bone marrow, interfering with cell differentiation, leading to a syndrome of bone marrow failure. AML is a consequence of genetic and epigenetic changes (point mutations, gene rearrangements, deletions, amplifications, and arrangements in epigenetic changes that influence gene expression) in hematopoietic precursor cells, which create a clone of abnormal cells that are capable of proliferating but cannot differentiate into mature hematopoietic cells or undergo programmed cell death. The diagnosis requires more than 20% myeloid blasts in the bone marrow and certain cytogenic abnormalities. Treatment will depend on age, comorbidities, and cytogenetic risk among the most frequent.
Insights
Acute myeloid leukemia (AML) is a diverse bone marrow cancer caused by genetic and epigenetic changes. Diagnosis involves identifying over 20% myeloid blasts and specific cytogenetic abnormalities for tailored treatment.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Acute myeloid leukemia (AML) is a complex blood cancer originating from myeloid precursor cells.
- It is characterized by uncontrolled proliferation and impaired differentiation, leading to bone marrow failure.
- Genetic and epigenetic alterations are the primary drivers of AML development.
Purpose of the Study:
- To provide a concise overview of Acute Myeloid Leukemia.
- To highlight the underlying causes and diagnostic criteria for AML.
- To emphasize the factors influencing treatment decisions in AML patients.
Main Methods:
- Review of existing literature on AML pathogenesis and diagnosis.
- Analysis of key genetic and epigenetic changes implicated in AML.
- Summary of diagnostic standards, including bone marrow blast percentage and cytogenetics.
Main Results:
- AML arises from clonal expansion of abnormal hematopoietic precursors.
- Diagnosis hinges on identifying >20% myeloid blasts and specific cytogenetic abnormalities.
- Treatment strategies are individualized based on patient age, comorbidities, and risk stratification.
Conclusions:
- AML is a heterogeneous malignancy driven by molecular abnormalities.
- Accurate diagnosis and risk assessment are crucial for effective AML management.
- Personalized treatment approaches are essential for optimizing patient outcomes in AML.
More Related Videos
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
08:00A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model
Published on: October 14, 2016
Related Concept Videos
01:15Differentiation of Common Myeloid Progenitor Cells
02:56Treatment Resistant Cancers